211 related articles for article (PubMed ID: 11820780)
1. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide.
Gault VA; O'Harte FP; Harriott P; Flatt PR
Biochem Biophys Res Commun; 2002 Feb; 290(5):1420-6. PubMed ID: 11820780
[TBL] [Abstract][Full Text] [Related]
2. Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo.
Gault VA; O'Harte FP; Harriott P; Flatt PR
Metabolism; 2003 Jun; 52(6):679-87. PubMed ID: 12800091
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.
Gault VA; Flatt PR; Bailey CJ; Harriott P; Greer B; Mooney MH; O'harte FP
Biochem J; 2002 Nov; 367(Pt 3):913-20. PubMed ID: 12150711
[TBL] [Abstract][Full Text] [Related]
4. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
O'Harte FP; Gault VA; Parker JC; Harriott P; Mooney MH; Bailey CJ; Flatt PR
Diabetologia; 2002 Sep; 45(9):1281-91. PubMed ID: 12242461
[TBL] [Abstract][Full Text] [Related]
5. Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.
O'Harte FP; Hunter K; Gault VA; Irwin N; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1674-82. PubMed ID: 17299087
[TBL] [Abstract][Full Text] [Related]
6. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
7. Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists.
Gault VA; Hunter K; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Flatt PR
Arch Biochem Biophys; 2007 May; 461(2):263-74. PubMed ID: 17428436
[TBL] [Abstract][Full Text] [Related]
8. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo.
Gault VA; Parker JC; Harriott P; Flatt PR; O'Harte FP
J Endocrinol; 2002 Nov; 175(2):525-33. PubMed ID: 12429050
[TBL] [Abstract][Full Text] [Related]
9. Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide.
Gault VA; Harriott P; Flatt PR; O'Harte FP
Biosci Rep; 2002; 22(5-6):523-8. PubMed ID: 12635849
[TBL] [Abstract][Full Text] [Related]
10. Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide.
Gault VA; Flatt PR; Harriott P; Mooney MH; Bailey CJ; O'Harte FP
J Endocrinol; 2003 Jan; 176(1):133-41. PubMed ID: 12525257
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
12. GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.
Irwin N; O'Harte FP; Gault VA; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR
J Med Chem; 2006 Feb; 49(3):1047-54. PubMed ID: 16451070
[TBL] [Abstract][Full Text] [Related]
13. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).
Irwin N; Gault VA; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR; O'Harte FP
Biol Chem; 2005 Jul; 386(7):679-87. PubMed ID: 16207089
[TBL] [Abstract][Full Text] [Related]
14. Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide.
Kerr BD; Flatt AJ; Flatt PR; Gault VA
Biochem Biophys Res Commun; 2011 Jan; 404(3):870-6. PubMed ID: 21184739
[TBL] [Abstract][Full Text] [Related]
15. Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Green BD; Gault VA; Greer B; Harriott P; Bailey CJ; Flatt PR; O'Harte FP
J Med Chem; 2005 Feb; 48(4):1244-50. PubMed ID: 15715491
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
17. Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes.
Gault VA; Hunter K; Irwin N; Greer B; Green BD; Harriott P; O'Harte FP; Flatt PR
Biol Chem; 2007 Feb; 388(2):173-9. PubMed ID: 17261080
[TBL] [Abstract][Full Text] [Related]
18. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
[TBL] [Abstract][Full Text] [Related]
19. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
[TBL] [Abstract][Full Text] [Related]
20. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
